Clinical Trial Update: EGESTA - Emergent GI Therapy for Severe, Complicated CDI Using Fecal Microbiota Transplant [NA]

View source ↗

Summary

The NCT02968511 trial EGESTA evaluating emergent GI therapy for severe, complicated Clostridioides difficile infection using fecal microbiota transplant has bee…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection

Drugs mentioned

• Fecal microbiota transplant (fecal microbiota transplant)

Snippet

Sponsor: Milton S. Hershey Medical Center | Conditions: C.Difficile Colitis | NA | Status: WITHDRAWN